T he DSM classificatory system for depressive disorders is widely viewed as having high utility in terms of its comprehensiveness in providing operational definitions of depressive syndromes, in assisting clinical management, and in providing a universal tool for psychiatric research. However, I will argue that both the DSM and ICD-10 are "systems" in name only and that they have outlived their usefulness. Their nosology is currently preventing advances in clinical management of and research on depressive disorders. I will mainly critique the DSM nosology of depression, with occasional reference to the ICD-10.
being conceptualized as an "it"-one type, and varying only by severity. In the DSM-IV, an MDE is defined in the absence of any formalized "minor" disorders, but we can assume that dysthymia, cyclothymia, and adjustment disorder with depressed mood exemplify the latter group. In the ICD-10, depressive disorders are classified as severe, moderate, or mild. In addition to a dimensional severity model, both systems also include other dimensional parameters (for example, persistence and recurrence). In the last decade, clinicians have also been encouraged to recognize the clinical salience-in terms of morbidity and disability-of even less severe dimensional expressions (in the form of subsyndromal and subclinical depressive conditions).
Such a model invites 2 questions. First, is the severity-based model valid? Second, how valid are the cutoff points that prevent individuals being overdiagnosed with false positives or underdiagnosed with false negatives? Each issue will be considered before the utility of decisions made on the basis of the DSM-IV criteria is examined.
Of course, it is possible to dimensionalize anything. Categorical conditions such as cancer can be dimensionalized along parameters such as severity or diffusion, and their staging clearly illustrates a dimensional model-but when is the dimensional and (or) categorical model the most informative for defining a disorder? An individual with a tumour or lump would prioritize knowing whether it is cancerous or not (a categorical status variable). If confirmed, only then do dimensional parameters (for example, How severe is it? Will it recur? How long will I live?) become salient. Thus, if there are categorical depressive conditions, categorical models are preferable for defining the condition. Dimensional second-order issues (for example, severity, duration, or level of impairment) may then be highly cogent, but they are unlikely to provide definitional power.
A dimensional model is only relevant if the conditions to be defined and distinguished are truly aligned along a defining continuum, and possibly-as a default option-if a truly categorical condition resists delineation and measurement by categorical techniques. However, the current dimensional model of depression encourages arbitrary clinical aphorisms (for example, ECT for severe depression, antidepressant drugs for moderate depression, and psychotherapy for mild depression). Can we not improve on such loose, and potentially erroneous, signals?
Decisions as to whether depressive disorders are best measured categorically or dimensionally are most effectively made by considering 2 issues, in essence reworking the deontological versus utilitarian ethical parameters. As usually applied, the deontological position weights whether conduct is right or wrong-independent of any consequences. The utilitarian argument considers whether the action can be justified as right in terms of its ultimate contribution (that is, does the end justify the means). In terms of a model for classifying depressive disorders, the respective components to consider are whether the model is intrinsically valid as opposed to whether it usefully informs us-irrespective of it being valid or invalid-about the disorder's cause, natural history and treatment differentiation. Currently, we assume the latter and put the former into the "too hard" basket. I suggest that the latter cannot be assumed and that the former is worth tackling.
Historically, debate about classifying the depressive disorders has been polarized around binary versus unitary views. The long-standing binary view argues for an endogenous (melancholic) type contrasted with a neurotic or reactive type (an imputed 2-category model). The unitary view is clearly a dimensional model, positing that multiple depressive conditions lie along a continuum of severity. A key question arises here: Why assume that only one model is required to explain the multifaceted world of the depressive disorders? In reality, depression can exist as a disease, a syndrome, or a reaction. Given such protean expressions, multiple (categorical and dimensional) models are almost certainly required.
While the ICD-10 system appears underpinned by a simple dimensional model, its components and modifiers allow 27 differing coding options. However, it occasionally appears to forget its dimensional base. For example, the F33.2 and F33.3 codes allow for recurrent episodes of endogenous depression and vital depression, albeit with neither of these conditions being defined or coded. The DSM-IV model is also a potpourri of dimensionally modelled conditions with multiple modifier options. It has many vague, illogical, and concatenated criteria. Its criteria are often operationalized at a low inference level, with some criteria sets having thin boundaries that overlap with other conditions. For unipolar disorders, modifiers and other parameters generate 14 different DSM-IV numerical codes for major depression alone, while multiple other expressions of depression are defined (for example, dysthymia, adjustment disorders, and depression secondary to medical illness). 
The DSM's Concatenated Descriptors
Descriptor concerns with the DSM-IV? Consider, for example, its MDE guilt criterion, which is defined as "feelings of worthlessness or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)" (1, p 327). Thus 2 somewhat differing constructs (worthlessness, which is ubiquitous to depression, and guilt, a more facultative component) are combined to create a concatenated descriptor. Further, unless delusions are viewed as extensions of a sense of worthlessness, a positive response to the guilt criterion subsumes multiple expressions that are difficult to conceptualize as existing within a dimension. Additionally, "excessive or inappropriate guilt" is also a criterion for MDE with melancholic features, and "delusions of guilt" is a criterion for MDE with psychotic features. Essentially, a patient with depression who has delusions of guilt meets criteria for 3 differing expressions of major depression, which is illogical for a dimensional model and also contributes to boundary problems. The DSM-IV's descriptor of melancholia-"distinct quality"-is also problematic. It is defined as a component of the depressed mood which is "distinctly different from the kind of feeling experienced after the death of a loved one" (1, p 384) . This is a negative rather than a positive definition, somewhat like defining ice hockey as different from baseball but leaving ice hockey undefined.
The DSM's Diffuse Category Boundaries
Boundary problems? In moving away from a subtyping model in the DSM-II system, the DSM-III system effectively argued for diagnostic decisions to be established on the basis of criteria-imposed cutoffs rather than on prototypic descriptions of clinical syndromes. Although the actual DSM-III MDE description (2, p 210-211) weights a set of endogeneity features indicative of a biological depressive condition, the guiding principle to the development of the DSM-III was to have clinical criteria "described at the lowest order of inference necessary to describe the characteristic features of the disorder" (2, p 7). Consequently, the diagnostic criterion bar for many items was set very low, risking inclusion of patients with less substantive disorders, while the vagueness of many criteria poses an intrinsic risk to reliability estimates. Further, rather than employing an exclusive model, the DSM dimensional model for the last quarter century for defining depression severity (in regard to major and "other" dimensional depressive conditions) also allows dimensional conditions to be superimposed on other conditions (for example, major depression superimposed on dysthymia to create so-called double depression). Boundaries between listed conditions often lack distinct cleavage. For example, several identical or similar criteria are used to define major depression, melancholia, and dysthymia. In the absence of any explicated model, and with the DSM system itself being atheoretical, any critique of the system is left to box with shadows. Such design issues run the risk of producing low reliability, and if a condition or entity cannot be defined reliably, its intrinsic validity, utility, and other secondary properties are usually compromised. Such issues will now be considered, particularly in relation to major depression.
DSM Categories and Nonspecific Results
Although the reliability of the whole DSM-III criteria-based system has rarely been considered, evaluations have not been inspiring. In providing a review of relevant studies, Kirk and Kutchins noted that "the scientific data used to claim success and great improvement simply do not support the claim" (3, p 83). Despite the DSM-III's new approach of implementing criteria-based diagnoses to prioritize reliability, those authors noted that "the reliability problem is much the same as [it] was 30 years ago" (p 83). If we narrow consideration to major depression alone, many studies demonstrate an unsatisfactory reliability. One US study (4) compared DSM-III major depression diagnoses made by psychiatrists and lay interviewers. A standardized interview schedule was used, and the kappa coefficient was 0.25, indicating that its reliability in defining major depression was low, even with standardized interview questions.
In terms of utility, major depression has no etiological specificity, with Hickie concluding that studies of those with major depression had "failed to demonstrate any coherent pattern or neurobiological changes," or "replicate key biological correlates across differing research groups, age cohorts and treatment settings" (5, p 39). Further, a diagnosis of major depression is not associated with any treatment specificity effect. Despite the fact that RCT data for major depression comprise the largest database in psychiatry, relevant metaanalyses (6) fail to differentiate treatments from one another in terms of their efficacy. For instance, old antidepressants appear as efficacious as new antidepressants, CBT appears as efficacious as IPT, antidepressant drugs appear as efficacious as CBT and IPT, and St John's wort appears as effective as antidepressant drugs.
The issue of nonspecific results is of even greater concern when considering placebo-controlled RCTs of antidepressant treatment modalities. There are more RCTs and metaanalyses of treatments for major depression than for any other psychiatric condition. The results of many of these studies risk being interpreted as inconclusive. In relation to RCTs of antidepressant drugs, Kirsch and others (7) analyzed data presented to the US FDA for all 6 antidepressants approved between 1987 and 1999. Of the 47 trials, 9 demonstrated no drug-placebo difference. For the remainder, the difference between antidepressant drug and placebo was 2 points on the Hamilton Depression Rating Scale, which the authors interpreted as being of questionable significance. Similarly, Khan and others (8) examined data submitted to the FDA from 52 pivotal placebo-controlled studies of antidepressants. In 50% of the trials, the antidepressant was indistinguishable from placebo. Similar results have been published for the so-called evidence based psychotherapies, with a metaanalysis of IPT (9) quantifying a nonsignificant trend across remission rates that indicated IPT to be only slightly superior to placebo.
These equipotent study results lead to an "everyone is a winner, everyone is a loser" conclusion. As noted by Holmes, they generate the Dodo bird verdict: "Everyone has won, and all must have prizes" (10, p 288), with practitioners of each modality able to claim that their treatment has been demonstrated as efficacious. The downside is that minimal differentiation of active treatment from placebo invites the interpretation that many antidepressant treatment strategies are no more than placebos themselves, a conclusion that would be quite reasonably rejected by clinicians.
Consequences of DSM-Generated Nonspecificity
These nonspecific study results have produced predictable consequences. In the absence of a logical rationale for treatment choice, other factors dictate causal postulates and treatment choices. Those who view major depression as underpinned by a chemical imbalance are inclined to prescribe an antidepressant drug, those imputing faulty cognitive schema tend to recommend CBT, and those judging social factors to be the depression's cause may initiate IPT or counselling. Therapy thus tends to be guided by the professional's disciplinary background or training rather than by characteristics of the disorder. The patient is fitted eclectically to a preferred therapy in a Procrustean manner rather than the therapy being chosen to fit the condition. Such a practice model would not be accepted in most other disciplines of medicine. For example, the size (dimensional model) of a lump is less salient than its pathology (whether it is cancer or not), and the severity (dimensional model) of pain is less salient than its cause.
To further examine the issue, allow me to reuse a "breathlessness" analogy (11 Thus, if the overall category (be it major dyspnea or major depression) effectively homogenizes differing constituent conditions, any study seeking to clarify the intrinsic status of the category (for example, disease, disorder, or a reaction), its causes, and its treatments will always be compromised-as will clinical management.
Background and a Reconceptualization
Although Goldney is sanguine about the DSM system being "the most clinically useful way in which to conceptualize mood disorders" (12, p 877), the nonpolemical material presented here clearly challenges both its conceptualization and its utility. The risk to any such critical enterprise is that it will be viewed as destructive, but our own research has sought to advance and employ an historically preferred model. The broad argument was presented in an earlier paper titled "Can Paradigms Lost Be Regained?" (13) and has since been extended (14) .
Historically, a binary model-contrasting a "more biological" entity (for example, endogenous depression or melancholia) with a neurotic or reactive depressive class-was long favoured. Attempts to prove this binary model failed, principally on methodological and analytic grounds; these have been extensively detailed (15) . For example, data sets of putative discriminating items had few truly specific melancholic items, while the inclusion of many items-most of which defined depression rather than the melancholic depressive subtype-effectively swamped the definitional capacity of the truly discriminating items. This resulted in a unimodal distribution of plotted scores, even though theorists argued that a bimodal distribution (or point of cleavage) was required to validate the binary model. Most commonly, factor or principal components analyses (for example, dimensional analytic strategies) were used instead of the multivariate analytic approaches more appropriate for the identification of categories. These dimensional analytic approaches increased the risk of depression being contrasted with anxiety or a nondepressed dimension rather than increasing the likelihood of melancholia being contrasted with nonmelancholic depressive conditions. However, in the absence of clear empirical support for the binary model, it was not appropriate then for the DSM-III Task Force committee to effectively resolve the unitarybinary debate by imposing a principally unitary model. Regrettably, that debate had focused exclusively on contrasting binary and unitary models. As noted earlier, this paper argues the need for multiple models to map a territory comprising putative diseases, disorders, and syndromes.
An Alternate Subtyping Model
The subtyping model advocated here seeks, when relevant, to define disorders on the basis of phenotypic description and (or) causal drivers. In some instances (for example, melancholia) the former informs us about the latter. The principal structural model here is a hierarchical one (13) positing 3 principal depressive classes, with 2 of these classes (psychotic depression and melancholic depression) having specific features and thus being distinguishable (where there are no specific class-defining features) from a heterogeneous nonmelancholic depressive class.
A "depressed mood" component is common to all 3 classes-albeit more severe in melancholia than in nonmelancholic depression, and even more severe in psychotic depression. However, because this mood component is ubiquitous (and varies dimensionally), it is not used to differentiate between the 3 classes, as occurs in dimensional systems. Melancholia is distinguished from the nonmelancholic depressive conditions by the presence of observable PMD, the phenotypic feature that we have operationally modelled as reflecting a central cognitive processing component with arborizing motoric "retardation" and "agitation" branches. PMD is quantified by the 18-item CORE measure, which has been strongly supported by studies as a reliable and valid measure of melancholia (with receiver operating characteristic analyses deriving an operational cutoff score) (15) ; these studies also provide support for observable PMD as being necessary and sufficient to the definition of melancholia. PMD is present in those with true melancholia (the necessary component) and differentiates melancholia from nonmelancholic disorders without the requirement to include so-called endogeneity symptoms (the sufficient component). In cases of psychotic depression, in which PMD is more severe than in melancholia, we incorporate psychotic features (for example, delusions, hallucinations, and overvalued ideas) as the specific class-defining phenotypic characteristic.
It is a hierarchical model in the sense that patients occupying the highest class (for example, those with psychotic depression) have all the features of those in the lower classes.
These phenomenological distinctions can effectively inform us about the etiology of melancholia. In this subtyping model, observable PMD is viewed as a surface (or recordable) marker of an underlying neuropathological process, indicating the likely site of the neurobiological perturbations, with melancholia sometimes reflecting functional changes in certain neurocircuits and, at times (especially in those who later develop a subcortical dementia), reflecting structural as well as functional changes (14) .
Although this hierarchical model is primarily structural (in differentiating 3 classes), my colleagues and I have suggested that it is likely to be underpinned and driven by differential functional processes (16) . Essentially, we speculate that there are likely to be 3 differential neurotransmitter contributions to each of the 3 classes, with psychotic depression having a greater perturbation of dopaminergic function, melancholic depression having a greater perturbation of noradrenergic neurotransmitter function, and the nonmelancholic disorders reflecting a greater perturbation of serotonergic neurotransmitter function.
The model therefore assumes the recruitment of differing proportions of key neurotransmitter functions to each of its 3 classes, functions that contribute to the phenomenology of psychotic and melancholic depression and, if valid, should contribute to treatment differentiation.
The Utility of the CORE System
As noted earlier, any model for classifying depression is best judged in terms of its utility. Here, utility is viewed as providing valid explanations regarding cause and also having treatment implications. If our hierarchical structural and functional models are valid, then we would anticipate differential responses to broad-spectrum and narrow-spectrum antidepressant approaches. Metaanalyses of treatments for psychotic depression (17, 18) indicate a 25% response to an antidepressant drug, a 30% response to an antipsychotic drug, an 80% response to combination antidepressant and antipsychotic drugs, and an 80% response to ECT, while other studies have suggested a placebo or spontaneous remission rate of 5%. This is a striking gradient and quite contrary to the equipotent findings quantified for treatment of major depression as defined by the DSM.
There is also reasonable evidence suggesting that those with melancholic depression have a low placebo response rate (in the order of 10%), do poorly with psychotherapy (as monotherapy), and benefit from physical treatments (for example, antidepressant medication or ECT). Application studies I conducted along with my colleagues have shown that differing antidepressant classes have differing efficacies for those with melancholia (19, 20) . For instance, comparing response rates for those receiving representative narrowaction antidepressants (for example, SSRIs) with response rates for representative broad-action antidepressants (for example, TCAs) demonstrated that the TCAs were distinctly more effective than the narrow-action SSRIs-and that this differential increased with age. Specifically, the responder rates for those with melancholia aged 46 years and younger were 38% for the TCA and 32% for the SSRIs; for those aged 46 to 60 years, respective rates were 44% and 21%; and for those aged 60 years and older, respective rates were 38% and 9%. We suggested that, as those with true melancholia age, their phenotypic picture changes in the sense that PMD becomes more distinctly severe (particularly for the motoric components), which reflects the recruitment of more monaminergic systems-presumably with greater noradrenergic and dopaminergic perturbation-and consequently reduces the capacity to respond to a narrow-action SSRI. This is an example of how the structural and functional models allow phenomenology, etiology, and treatment response to be wedded into an interactive working hypothesis. Our treatment findings are deceptively important for those with melancholia, since narrow-action antidepressants are the most commonly prescribed drugs for melancholia, which risks a low response rate and-as is commonly observed in our clinical practice-a false diagnoses of treatment-resistant depression.
Modelling the Nonmelancholic Disorders
For the nonmelancholic disorders, developing an appropriate model (14) is more difficult for 2 principal reasons. First, as noted earlier, in contrast to psychotic and melancholic depression, there are no class-specific features, which reduces the capacity for phenotypic description. Thus we must turn to primary differentiation by modelling the causal drivers, which we conceptualize as stress and temperament or personality style. Second, as both these constituents are intrinsically dimensional, it is unlikely that they build to "pure" depressive types, so the modelling problem here involves addressing the interdependencies in a way that would ensure sufficient cleavage to identify clinically meaningful conditions.
For some nonmelancholic conditions, we assumed that stress effects the principal contribution-with both acute and chronic expressions. The acute stress-related disorders correspond historically to the concept of reactive depression, but studies have indicated that the salience of the stressor is actually more influential than its severity. This has led to the development of a "key and lock" model for these reactive disorders. We hypothesized that certain developmental experiences acting on the individual's self-esteem create a diathesis (lock) that predisposes the individual to develop an acute reactive depression if faced with a mirroring precipitating event (key) in later years. For example, a harsh and judgmental father may establish a "vulnerability" lock in his daughter. In later years, she may be particularly vulnerable and at risk of developing a reactive depression when someone in authority makes a critical or judgmental comment; effectively, the key opens the lock. By contrast, for the chronic nonmelancholic depressive disorders, we posit a "learned helplessness" model. This model assumes that certain ongoing "uncontrollable" events (principally social and interpersonal) can cause the individual to feel that he or she has no capacity to influence outcome in his or her life, resulting in a depressed mood, loss of motivation, and chronic depressive symptoms.
For other nonmelancholic conditions, we assumed that certain personality and temperament styles provide the greater contribution. We then sought to move beyond the historical concept of neurotic depression (where neurosis was simplistically viewed as effecting risk for depression) to identify those personality and temperament styles that predispose individuals to the nonmelancholic depressive disorders. Strategies initially involved "bottom up" investigations (reflecting clinical observations and respecting constructs identified in the literature), and we identified a putative set of 8 candidate personality styles. We then developed a self-report questionnaire (the Temperament and Personality Questionnaire, available online at http://www.blackdoginstitute.org.au). When an 8-factor solution was imposed, we found strong confirmation of the putative constructs since more than 90% of the items corresponded with their a priori allocated personality construct (14, 21) . The 8 personality styles were labelled: Anxious Worrying (or internalized high trait anxiety), Self-Criticism, Sensitivity to Rejection, Irritability (or externalized high trait anxiety), Self-Focused (or hostile), Perfectionism, Personal Reserve, and Social Avoidance. In our clinical application monograph (14) , we explicate pluralistic treatment strategies for depressive conditions associated with these 8 differing personality styles-and for the acute and chronic nonmelancholic disorders-with the treatment strategies designed to address and modify the causal drivers. For example, if the condition is an acute reactive depression, the therapist might seek (via nondrug strategies) to neutralize its impact or reduce its salience to (and cognitive impact on) the individual. Alternatively, if these strategies failed, the therapist might consider strategies (including an antidepressant drug) to decrease the stressor's depressogenic impact.
However, rather than argue that the 8-factor model is necessarily a finite one, we imposed varying factor numbers ranging from the 2-factor through to the 8-factor solution. This arborizing model allows for the identification of higher-order molar constructs (for example, neuroticism and introversion) and lower-order facets, as well as identifying the origins of the latter (for example, rejection sensitivity emerging from a higher-order neuroticism construct). Further, the model allows for correspondence to be traced with the dominant 5-factor model of personality functioning. Finally, it has enabled us to argue (21) that research inquiries might benefit from applying a flexible model of personality that concedes that higher-order personality constructs may be more relevant for pursuing certain research questions and that lower-order constructs could be relevant for other research questions. Earlier depression researchers focused on the higher-order construct of neuroticism. However, in some of our inquiries, we have found greater explanatory power when using a lower-order solution. For example, to delineate and confirm the clinical picture of atypical depression (where the individual with depression has a personality style of rejection sensitivity as well as the atypical features of hypersomnia and hyperphagia), we were required to proceed to the 6-factor solution to ensure clear delineation of the rejection sensitivity personality construct.
Current analyses pursue how far we can proceed with a spectrum model for those with nonmelancholic personality-based disorders. Our earlier research (see reference 14 for an overview) allowed us to conceptualize and model 3 spectrum models (those with personality styles of internalized anxious worrying, those with externalized anxious irritability, and those with a more hostile, self-focused personality style). For example, we observe clinically that, when exposed to a stressful event, those with a personality style of anxious worrying tend to have such a personality style amplified and therefore develop a depressive syndrome infiltrated with components of autonomic arousal and worrying. Those with an irritable personality style, by contrast, tend to be more irritable and crabby when suffering from depression. Those who have a self-focused personality style tend, when suffering from depression, to externalize their frustration, aggression, and hostility and create considerable collateral damage. This spectrum model (with personality style amplified by stress and expressed by varying coping and homeostatic responses) has the capacity to provide "fuzzy set" phenotypic patterns. However, as personality styles are interdependent to varying degrees, we do not believe that such nonmelancholic disorders allow pristine separation from each other or that they form pure types. Thus a dimensional model has to be preferred over any categorical model for their definition and modelling, but the fuzzy set clinical patterns (or what anthropologists describe as thick descriptions) can assist clinical formulation of the candidate personality contributing to the nonmelancholic depressive disorders-and thus provide a therapeutic lever.
Treatment Implications for the Nonmelancholic Disorders
In contrast to our data demonstrating differential efficacy for narrow-action and broad-action antidepressants for melancholic depression, those same studies (19, 20) showed similar levels of efficacy for narrow-action and broad-action antidepressants in the treatment of the depressive disorders. We therefore suspect that response rates for the whole nonmelancholic class are comparable for all principal drug and nondrug treatment modalities-as is evident in the analyses of treatment studies for major depression. Thus the task is to determine the relevance of differing treatment options for the differing constituent stress-related and personality-related conditions, which we have detailed in our recent monograph (14) . Such proposals are driven more by clinical opinion than by empirical studies, for obvious reasons: using major depression as the reference disorder in the literature disallows "unpacking" treatment differentiation effects across class members. Although our model is plausible and its flexibility respects the heterogeneity of the nonmelancholic disorders, it is clearly exploratory and requires tests of its utility. At a fine-focused level, it is not readily amenable to RCT evaluation. The whole model (comprising quite differential principal strategies for distinctive psychotic, melancholic, and nonmelancholic depressive disorders) is, however, able to be tested by taking the responder rates in those assigned to such an intervention and comparing them with those assigned to a single universal comparator intervention-be it a drug-based or psychotherapy-based modality. We are currently progressing with this strategy.
Conclusion
Our objective is to advance a subtyping model for the depressive disorders that has greater causal explanatory power than the current dimensional DSM-IV and ICD-10 models, and then to derive a matrix of treatments for the constituent conditions that are tested in subgroups, so that any evidence is not attenuated by the white noise of diffuse or inaccurate definition. We argue that potential biological markers are likely to be swamped by the DSM's ill-defined groupings and suggest that, because a nonspecificity model now dominates theory and practice, dispiriting results are to be anticipated. Thus, if treatments are tested as if they have universal application (that is, using a nonspecific model) for a nonspecific condition (such as major depression), nonspecific equipotency results will be derived-as is evident in the literature. Our subtyping model advocates a "horses for courses" approach, as opposed to viewing any treatment (be it drug or psychotherapy) as having universal application. It seeks to weight clinical observation and common sense-and invites your consideration.
